ACTIVITIES REPORT FOR THE QUARTER ENDED 30 SEPTEMBER 2026

HIGHLIGHTS

- **AUD$3.5 million share of Florida Medicaid Imaging Repository MOU:** Memorandum of Understanding (MOU) executed with Florida International University (FIU) to design, deliver, and operate a secure medical imaging repository on 3DICOM®, funded by a US$3.0 million State of Florida appropriation.
- **Continued progress across the Provider Network Solutions (PNS) network:** 1,000 contracted 3DICOM MD® licenses deployed. This agreement is due for renewal by 31 December 2026; discussions on renewal and expansion are ongoing.
- **Development and validation of ImageIQ:** Continued development and validation of ImageIQ, the Company's AI-powered imaging appropriateness module.
- **Medical Device Single Audit Program (MDSAP):**Certification retained following a surveillance audit; HITRUST certification preparations progressed.
- **Enterprise infrastructure and scalability:** Continued technological strengthening of the 3DICOM® platform, including an independent architecture review to support larger healthcare networks and infrastructure deployments.
- **Healthy balance sheet:** $8.14 million in cash at 30 September 2026, with no debt. Net operating cash outflow of $1.9m for the Quarter. A$0.47m of R & D tax incentive still to be received in coming month.
- **Post September-Quarter end:** Australian patent granted for the Medical File Transfer System underpinning the Company's MFTP technology (1 October 2026).

Singular Health Group Limited (ASX: SHG) ("Singular Health" or "the Company") made strategic and commercial progress during the September 2026 Quarter. The key development was the Memorandum of Understanding (MOU) with Florida International University (FIU) for the delivery of a medical imaging Repository utilising 3DICOM®, to support Florida Medicaid system: the Company's first State-funded program and a step up in scale from its physician license deployments.

Medical imaging in the US is fragmented across providers, and scans that cannot be found are often repeated. Health plans and State Medicaid programs carry much of that cost. Singular Health's strategy is to prove its FDA-cleared 3DICOM® platform and proprietary Medical File Transfer Protocol (MFTP) technology across considered, targeted deployments in Florida, Texas and Puerto Rico, to measure the outcomes, and to subsequently use that evidence to expand to further networks, health plans and States.

The PNS deployment established that a network will pay for the platform; the Florida Repository is designed to measure what it saves, with the subsequent data anticipated to be used as validation for future customers.

Florida Medicaid Medical Imaging Repository

On 29 September 2026, Singular Health announced a MOU with FIU to design, deliver and operate a secure Medical Imaging Data Repository ("Repository") supporting providers that serve Florida Medicaid beneficiaries, built on the Company's 3DICOM® platform and MFTP technology.

Under the MOU, Singular Health's proposed share is approximately US$2.55m (A$3.5m). The MOU is non-binding in nature, except that the parties are legally bound to enter into definitive binding agreements based

on the minimum terms set out in the MOU. Payments under the MOU are to be made on agreed milestones, with the full amount payable by 30 June 2027 subject to delivery. The Company expects to deliver the project primarily with its existing team and to recognise the revenue in FY27.

The final phase of the project is a clinical and economic validation pilot in a defined Florida Medicaid population, designed to measure whether shared access to prior imaging reduces duplicate scans and their cost.

Measured evidence of this kind is central to how health plans and State programs evaluate imaging interoperability, and underpins the Company's proposed savings-share revenue model. The underlying data will be owned by the State of Florida; Singular Health expects to be able to use the resulting success metrics with health plans and other State programs.

Provider Network Solutions (PNS) Contract Update

PNS is the Company's largest customer agreement. 1,000 3DICOM MD® licences, contracted at US$800 per physician per year have been deployed across the PNS network, with the Company focused on utilisation and clinical workflow integration.

The enterprise agreement is due for renewal by 31 December 2026. During the Quarter, Singular Health continued discussions with PNS on renewal and potential expansion, including deployment of new licences and broader adoption across the PNS network.

Other US deployments

Life Radiology (Florida): 3DICOM® Gateway and 3DICOM® Patient continued in operation, replacing CDs with secure digital access to imaging for patients and referring providers. The Company is monitoring utilisation and patient adoption to provide potentially supportive data for further diagnostic imaging centre deployments.

Miami-Dade County Public Schools (M-DCPS): Implementation and onboarding continued for the paid 3DICOM® EDU pilot across five technical colleges (access for up to 150 students and instructors), the third largest public school district in the US, delivered with US distribution partner CG1 Solutions. The educational pilot is designed to support anatomy education and healthcare training programs.

US Commercial Pipeline

During the September Quarter, Singular Health continued to progress commercial engagement with healthcare providers, health plans and strategic partners across the United States and Puerto Rico, including Triple-S, regarding the deployment of its imaging sharing infrastructure and utilisation management capabilities. The company is pursuing a partner-led approach, using established networks and distribution partners rather than building a large direct salesforce in-house, in each market. These opportunities remain at discussion or pilot stage.

Product, Platform and Certification

ImageIQ: Development and validation continued, including workflows for primary care providers, utilisation management teams and radiology benefit managers. Where 3DICOM® Gateway finds prior imaging before a new scan is ordered, ImageIQ is designed to help clinicians select the appropriate examination in the first place. ImageIQ is not yet commercially released and is intended as an add-on for networks already connected to 3DICOM®.

Platform scalability: The Company is well under way in its independent testing of its solution architecture, to strengthen and support larger network and infrastructure deployments.

Quality and security: The Company passed an MDSAP surveillance audit, retaining its certification, and progressed preparations for HITRUST certification, a security assurance framework widely used by US health plans and providers.

Financial and Business Activities

Cash at 30 September 2026 was A$8.14 million (30 June 2026: A$10.07 million), with no debt.

Net cash outflows from operating activities were A$1.918 million, comprising staff costs (A$1.020 million), administration and corporate costs (A$0.445 million), research and development ($0.346 million), product and manufacturing costs ($0.221 million), and advertising and marketing ($0.064m). There were several one-off and timing-related payments, including a KPI bonus to the Managing Director and further research and development costs for future enhancement projects. Payments to related parties during the quarter totalled A$132,000, comprising A$85,000 paid to the Managing Director (including the KPI bonus) and A$47,000 in Non-Executive Director fees, as disclosed in item 6.1 of Appendix 4C.

Customer receipts during the Quarter totalled A$10,000, noting the US$800k PNS payment was received in the previous financial year. Singular recognises and bills licence revenues in accordance with the underlying customer agreements. Interest income contributed A$168,000.

The A$0.47m R&D tax incentive refund has not yet been received and is expected to be received in the current December Quarter.

Investing outflows of A$0.26 million comprised A$0.25 million in payments to capital contribution to acquire controlling 60% ownership in the Singular Imaging Solutions USA LLC (the PNS SHG JV reselling entity.) The exercise of share options raised A$0.257 million.

Based on the September Quarter's net operating cash outflow, the Company had approximately 4.25 quarters of available funding as at 30 September 2026. This excludes any receipts under the Florida Repository, which remain subject to definitive agreements.

Activities Subsequent to Period End

Investor Engagement

On 12 and 13 October 2026, the Company presented at the Canaccord Genuity Drug & Device Conference in Noosa, Queensland and participated in meetings with institutional investors.

Outlook

The Company's priorities for the December 2026 Quarter are to progress execution of definitive agreements with FIU and commence Repository delivery, progress the PNS renewal anticipated by 31 December 2026, and continuing ImageIQ validation.

Each is a step towards demonstrating measurable clinical and economic outcomes that can support adoption by further networks, health plans and States.

Authorised for ASX release by the Board of Directors.

Ends

For further information contact:

Denning Chong
Managing Director & CEO
support@singular.health
1300 167 795

Paul Berson
Investor Relations
paul@corporatestorytime.com
+61 421 647 445

About Singular Health

Singular Health is an ASX-listed (ASX: SHG) medical technology company which is working to create seamless and integrated healthcare ecosystem product offerings which enable the unlocking of the full value of medical imaging records, enabling universal access to images, and promoting interoperability to maximise patient outcomes, and reducing unnecessary and duplicate imaging costs.

Singular Health's 3DICOM® software solutions empower patients and practitioners to better visualise, communicate, and understand medical imaging data. 3DICOM MD® is cleared for diagnostic use in the United States.

To learn more, visit https://singular.health and https://investors.singular.health/

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Singular Health Group Limited	
ABN	**Quarter ended ("current quarter")**
58 639 242 765	30 September 2026

		Current quarter $A'000	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	10	10
1.2	Payments for		
	(a) research and development	(346)	(346)
	(b) product manufacturing and operating costs	(221)	(221)
	(c) advertising, marketing and investor relations	(64)	(64)
	(d) leased assets	-	-
	(e) staff costs	(1,020)	(1,020)
	(f) administration and corporate costs	(445)	(445)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	168	168
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other	-	-
1.9	**Net cash from / (used in) operating activities**	**(1,918)**	**(1,918)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	(249)	(249)
	(b) businesses	-	-
	(c) property, plant and equipment	(9)	(9)
	(d) investments	-	-
	(e) intellectual property	-	-

		Current quarter $A'000	Year to date (3 months) $A'000
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other	-	-
2.6	**Net cash from / (used in) investing activities**	**(258)**	**(258)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues/unissued of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	257	257
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other – lease payments	-	-
3.10	**Net cash from / (used in) financing activities**	**257**	**257**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	10,069	10,069
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,918)	(1,918)

		Current quarter $A'000	Year to date (3 months) $A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(258)	(258)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	257	257
4.5	Effect of movement in exchange rates on cash held	(8)	(8)
4.6	**Cash and cash equivalents at end of period**	**8,142**	**8,142**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	737	1,764
5.2	Call deposits	7,400	8,300
5.3	Bank overdrafts	-	-
5.4	Other (Bank Guarantee)	5	5
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**8,142**	**10,069**

6.	**Payments to related parties of the entity and their associates**	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	132
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	-

- Aggregate amount salary paid to Managing Director ($85k), and Non-Executive Director fees of ($47k).

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	**-**	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

-

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,918)
8.2	Cash and cash equivalents at quarter end (item 4.6)	8,142
8.3	Unused finance facilities available at quarter end (item 7.5)	nil
8.4	Total available funding (item 8.4 + item 8.5)	8,142
8.5	**Estimated quarters of funding available (item 8.6 divided by item 8.3)**	**4.25**

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

27 October 2026

Date: .....

The Board of Directors

Authorised by: .....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.